Prof. Valeria Santini, an expert on MDS from the University of Florence, discusses what we currently know about
genetic mutations and
cytogenetic changes associated with
better myelodysplastic syndromes (
MDS)
treatment outcomes. For example, changes in chromosome 5 (some
5q deletions) can indicate a favorable response to treatment with lenalidomide. A mutation in the gene
SF3B1 can also indicate a good prognosis. Prof. Santini discusses the need for transfusion and the role of multiple mutations.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.